EUVIMEDEUVIMED entdecken
Crossref

Single‐arm trials for US Food and Drug Administration cancer drug approvals

Mary Beth Nierengarten

Cancer · 2023

DOI: 10.1002/cncr.34830 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2023. Verfasst von Mary Beth Nierengarten. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents. Die Arbeit nennt 3 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, we explore why using single‐arm studies for accelerated US Food and Drug administration approvals can help get drugs previously approved for other uses to patients with cancer. In addition, new studies show that adherence to evidence‐based surgical metrics improves long‐term outcomes in patients with early‐stage lung cancer, and lung cancer screening based on personal lung cancer risk is more cost‐effective than screening based on age and smoking history.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntineoplastic AgentsUnited StatesHumansPharmaceutical PreparationsDrug ApprovalUnited States Food and Drug Administration

Substanzen

Pharmaceutical PreparationsAntineoplastic Agents

Zitieren

APA

Nierengarten, M. B. (2023). Single‐arm trials for US Food and Drug Administration cancer drug approvals. Cancer. https://doi.org/10.1002/cncr.34830

Vancouver

Nierengarten MB. Single‐arm trials for US Food and Drug Administration cancer drug approvals. Cancer. 2023. doi:10.1002/cncr.34830

BibTeX
@article{Nierengarten2023,
  author = {Nierengarten, Mary Beth},
  title = {Single‐arm trials for US Food and Drug Administration cancer drug approvals},
  journal = {Cancer},
  year = {2023},
  doi = {10.1002/cncr.34830}
}
Kostenlos starten →